Literature DB >> 6169655

IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma.

G D Mathew, L F Qualtiere, H B Neel, G R Pearson.   

Abstract

Immunoglobulin fractions containing antibodies to the Epstein-Barr virus (EBV) were isolated from different sera and tested in the antibody-dependent cellular cytotoxicity (ADCC) assay. All cytotoxic activity resided in the IgG fraction. IgA antibodies were not cytotoxic in this assay against cells expressing the EBV-induced membrane antigen complex. However, IgA antibodies were able to block the IgG-mediated ADCC reaction, indicating that the IgA and IgG antibodies recognized the same EVB-specific antigenic determinants. This was supported by results from radioimmune precipitation experiments. Our findings suggest that low ADCC titers previously identified in the sera of patients with nasopharyngeal carcinoma (NPC) who had a poor prognosis could be due to the blocking activity of IgA antibodies. The results further suggest that IgA antibodies are detrimental to the patient with this disease, if one assumes that ADCC functions in vivo in immunity to this tumor

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6169655     DOI: 10.1002/ijc.2910270208

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Colostrum of healthy mothers contains broad spectrum of secretory IgA autoantibodies.

Authors:  Jaroslava Pribylova; Klara Krausova; Ingrid Kocourkova; Pavel Rossmann; Klara Klimesova; Miloslav Kverka; Helena Tlaskalova-Hogenova
Journal:  J Clin Immunol       Date:  2012-07-10       Impact factor: 8.317

2.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Novel HIV vaccine strategies: overview and perspective.

Authors:  Yehuda Z Cohen; Raphael Dolin
Journal:  Ther Adv Vaccines       Date:  2013-09

Review 4.  Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases.

Authors:  M Kilian; J Mestecky; M W Russell
Journal:  Microbiol Rev       Date:  1988-06

5.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

Review 6.  Complex immune correlates of protection in HIV-1 vaccine efficacy trials.

Authors:  Georgia D Tomaras; Stanley A Plotkin
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 7.  HIV antibodies for treatment of HIV infection.

Authors:  David M Margolis; Richard A Koup; Guido Ferrari
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

8.  Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy.

Authors:  A Faggioni; C Corradini; G Barile; G Cardi; V Ciarniello; M Venenzoni; C Zompetta; M Maurizi; G Paludetti; V Manzari
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

9.  Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

Authors:  Georgia D Tomaras; Guido Ferrari; Xiaoying Shen; S Munir Alam; Hua-Xin Liao; Justin Pollara; Mattia Bonsignori; M Anthony Moody; Youyi Fong; Xi Chen; Brigid Poling; Cindo O Nicholson; Ruijun Zhang; Xiaozhi Lu; Robert Parks; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Peter B Gilbert; Jerome H Kim; Nelson L Michael; David C Montefiori; Barton F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-09       Impact factor: 11.205

Review 10.  Fc-fusion proteins: new developments and future perspectives.

Authors:  Daniel M Czajkowsky; Jun Hu; Zhifeng Shao; Richard J Pleass
Journal:  EMBO Mol Med       Date:  2012-07-26       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.